How about all this?
What about some information that is not being distributed at a rapid cost? With everything online, COVID-19 immunity feels a bit like a priceless commodity.
Creating a vaccine is not as complicated as creating one, but it is not far off. To beat the coronavirus, the vaccine must be cheap and available in large quantities so that everyone gets a dose. But it must also return enough of a profit to cover the cost of development and production. In an August 5 investor calls, NPR reports, the CEO of Moderna said the company had made deals with some countries with $ 32 and $ 37 small order doses, with lower prices for larger quantities.
How is Inovio doing balance in this tight grip? Broderick said she thinks it is going well, adding that “on a large scale, we think our cost of goods will be really very affordable”;.
The process of DNA production is actually not that different from drinking beer, she said, but instead of yeast throwing away sugar and leaving alcohol, you have E. coli bacteria acting as a mini-factory for make the vaccine. Injecting pieces of DNA made by a bacterium into human cells may sound a little strange, but it really is not a new concept. Making DNA and adding it to cells has long been an important skill for basic scientific research – it is simply reproducing existing technology.
With the exception of a special use waiver in China, no vaccine is currently available to the public. But if you are interested in inserting the arm for science, Broderick said you can join in the clinical trials. The Inovio website has a link this will take you to the government page, where you can join the waiting list. The vaccine cannot move forward without more testing, and more evidence.
A clinical trial is a controlled scientific study, so enrollment does not guarantee acceptance. And just because half of the participants will get a mock vaccine, even joining the trial does not mean you will really be immunized.
COVID-19 has not affected everyone equally. The elderly are particularly at risk, and black and Latino people, many working in essential jobs during the pandemic, have fallen ill and are dying at higher rates.
“If you test [of] the vaccine does not really reflect the demographics, the population for which it was created, it is almost a false picture, “Broderick said. Inovio is trying to address this in its trial construction, she said.
“It has been something we have been very, very aware of to move forward in the next round of clinical testing, is that those groups are actively encouraged to join the clinical trial.”
Daniel Kulp, a researcher at Wistar who is continuing work on the COVID-19 vaccine, said he thinks many different vaccines will be available.
“I think it’s also a benefit,” Kulp said, “because they’ll all be a little different in what kind of immunity they run and what kind of security they have.”
With so many vaccines vying to hit the market, the best case scenario looks at people all over the world to have some safe options as soon as possible. Not just for Inovio but for her personally, that’s too big, Broderick said.
“As a mother, as a citizen, you can not help but get out of the situation we are in, that the whole world is in the moment,” she said.
Patel, too, sees the importance of the work. “Having a vaccine, ours in addition to other candidates, I think will really help people feel more comfortable and bring them back to normal daily life and being the human beings we are.”